Elsevier

Genetics in Medicine

Volume 19, Issue 12, December 2017, Pages 1317-1322
Genetics in Medicine

Original Research Article
Do the data really support ordering fragile X testing as a first-tier test without clinical features?

https://doi.org/10.1038/gim.2017.64Get rights and content
Under a Creative Commons license
open access

Abstract

Purpose

Current guidelines recommend first-tier chromosome microarray analysis (CMA) and fragile X syndrome (FX) testing for males with isolated intellectual disabilities/learning delay (ID/LD) and autism spectrum disorders (ASDs).

Methods

Males in our clinic with ID/LD or ASD (310) were analyzed for positive results from CMA and/or FX testing.

Results

CMA detected abnormalities in 29% of males with ID/LD and only 9% of males with ASD (including variants of uncertain significance and absence of heterozygosity). When males with ID/LD were tested for FX, the detection rate was 2.5% (2 of 80). Both patients had dysmorphic features and maternal family history. No males with ASD had positive FX test results.

Conclusions

The detection rate of CMA in males with isolated ID/LD in this study was higher than in the literature (10–20%). CMA results for males with ASD (9%) and FX testing for males with ID/LD (2.5%) overlap with the literature (7–10% and 2%, respectively). The yield of FX testing for patients with ASD was zero, which is close to that of the literature (0.5–2%). These results suggest that FX testing as a first-tier test may not be necessary, unless other criteria suggest FX.

Keywords

autism
chromosomal microarray analysis
fragile X syndrome
learning delay
intellectual impairment

Cited by (0)